ClinicalTrials.gg
CompletedNCT06810245Updated Mar 18, 2026

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

A Phase 1 interventional study of PIPE-791 and Placebo in Chronic Osteoarthritis Pain and Chronic Low Back Pain, sponsored by Contineum Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Contineum Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,283 studies in Chronic Pain with a site in United States — 258 open to participants now, 349 under way, 7 of them phase 3. Chronic Pain · United States.

Enrollment
640th of 1,092
43 · median 60
Started
2025
with 91 others
Phase 1
63 of 1,283
11 open now
Registered
1,132nd of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 640th largest by enrollment of the 1,092 interventional ones that give a count, is one of 92 that started in 2025, is one of 63 in phase 1, and was the 1,132nd registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

258 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

253 more — sign in →

All 258 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP.

Subjects will:

  • Complete a washout period to stop their current pain medications.
  • Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks.
  • Record pain levels and track dosing in a daily e-diary.
  • Visit the clinic for checkups and lab tests throughout the study.
  • Complete phone assessments during the treatment periods.
Read the detailed description

This is a double-blind, randomized, placebo-controlled, 2-period crossover study designed to evaluate the safety and tolerability of PIPE-791 in approximately 20 adults with COAP and 20 adults with CLBP (with or without painful lumbosacral radiculopathy). Subjects will be randomized to receive either PIPE-791 or placebo daily for 4 weeks, followed by a crossover to the alternate treatment assignment for an additional 4 weeks.

A washout period of all chronic pain medications is required prior to randomization. Rescue medications, including acetaminophen and naproxen, will be permitted during the study.

Subjects will complete regular clinic visits for safety assessments, laboratory testing, and physical evaluations. Daily pain scores and dosing information will be reported by subjects using an electronic diary (e-diary).

All subjects who complete dosing will have a post-treatment safety follow-up/end of study (EOS) phone visit approximately 28 days after the last dose of study drug. Subjects who prematurely discontinue dosing and all assessments from the study will have an early termination (ET) visit as soon as possible on or after their last dose of study drug.

The total duration of participation, including screening, treatment, and follow-up, is approximately 16 weeks.

03

Conditions studied

  • Chronic Osteoarthritis Pain
  • Chronic Low Back Pain

Keywords

  • chronic pain
  • pain
  • low back pain
  • osteoarthritis pain
  • osteoarthritis
  • pain management
  • neuropathic pain
  • CLBP
  • COAP
  • OA
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Male or female 18 to 70 years of age, inclusive, at the first Screening visit.
  • Only one of the following chronic pain diagnoses at least 6 months prior to Screening:
  • Osteoarthritis of the knee OR low back pain (with or without painful lumbosacral radiculopathy)
  • Plain radiographs of the knee or lumbar spine consistent with diagnosis within 9 months prior to or during Screening.
  • History of related daily pain for at least 6 months prior to Screening.
  • Have a \<40 (inclusive) at Screening.
  • Willing to maintain a consistent regimen of any ongoing (stable format and frequency for the duration of study participation) non-pharmacologic pain-relieving therapies.
  • Willing to discontinue medications taken for chronic pain conditions and usage of transcutaneous electrical nerve stimulation for the duration of the study.
  • Male or female subjects with agree to comply with a highly effective method as per protocol through 90 days after last study drug administration.
  • Subjects taking systemic hormone-replacement therapy must be on a stable dose and regimen for at least 1 month prior to Screening.
  • General good medical health with no or relevant abnormalities except those attributed to the underlying chronic pain condition, including medical history, physical exam, vital signs, , and laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the Investigator.
  • Ability to use an eDiary to record daily pain scores.

Key Exclusion Criteria

  • History of chronic pain after multiple failed treatments as determined by the Investigator (e.g., no response to all of the following: surgery and/or nerve blocks, a regimen of at least two non-opioid pharmacotherapies, and physical rehabilitation, and weak opioids).
  • Concurrent diagnosis of fibromyalgia or evidence of chronic widespread pain, or other pain that may interfere with the assessment of CLBP or COAP.
  • Demonstrated noncompliance recording daily Numerical Rating Scale (NRS) scores during Screening.
  • Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest, e.g., an ablation procedure.
  • Received capsaicin treatment (e.g., Qutenza) within the past 3 months prior to screening.
  • Have surgery planned during the study for any reason, related or not, to the disease state under evaluation.
  • Are non-ambulatory (use of assistive devices is allowed).
  • History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis.
  • Diagnosed with OA during childhood or adolescence, including post-traumatic OA or OA due to genetic (e.g., hip dysplasia) or congenital (e.g., metabolic disorders) conditions.
  • History of or clinical signs or symptoms of active joint infection, crystal disease of the knee, or a history of arthritis due to crystals (e.g., gout, pseudo gout).
  • History of prior lumbar or thoracic spine surgery (e.g., discectomies, laminectomies, foraminotomies, or fusion).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Active followed by Placebo

    Drug: PIPE-791 · Drug: Placebo

  • Experimental
    Placebo followed by Active

    Drug: PIPE-791 · Drug: Placebo

Interventions

  • PIPE-791 tablet, taken once daily for 4 weeks

  • DrugPlacebo

    Placebo tablet, taken once daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Number of subjects with Treatment-emergent adverse events (TEAEs)

    The number of subjects with TEAEs will be summarized in each treatment arm and compared within each treatment period.

    Time frame: For Treatment Period 1, from Baseline (Day 1) to End of Treatment Period 1 (TP1; Day 29), for Treatment Period 2, from Baseline of Treatment Period 2 (TP2; Day 29) to End of TP2 (Day 57).

07

Study locations

5 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Drug Studies America
    Marietta, Georgia 30060, United States
  • Drug Trials America
    Hartsdale, New York 10530, United States
  • Altoona Center of Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
08

References and documents

Publications

  • Chen A, Baccei C, Baccei J, Broadhead A, Lorrain KI, Poon MM, Roppe J, Schrader TO, Stebbins KJ, Valdez L, Xiong Y, Lorrain DS. Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders. J Med Chem. 2026 Jul 9;69(13):15888-15927. doi: 10.1021/acs.jmedchem.6c01049. Epub 2026 Jun 29. PubMed 42370792 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jan 2026, 11 months.

Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 11 months is above that.

Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Feb 5, 2025
StartActual
Feb 4, 2025
Primary completionActual
Jan 20, 2026
CompletionActual
Jan 20, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06810245
Lead sponsor
Contineum Therapeutics
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Feb 4, 2025
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026
Last update
Mar 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PIPE-791

Start the discussion